Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

BACKGROUND: Sarilumab is a human immunoglobulin G1 anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor α. This bridging study assessed the efficacy and safety of sarilumab + methotrexate (MTX) in Japanese patients with acti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Res Ther
Main Authors: Tanaka, Yoshiya, Wada, Kazuteru, Takahashi, Yoshinori, Hagino, Owen, van Hoogstraten, Hubert, Graham, Neil M. H., Kameda, Hideto
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6425658/
https://ncbi.nlm.nih.gov/pubmed/30894208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-019-1856-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados